L'Oréal announced the purchase of a 10% share in Galderma Group AG from Sunshine SwissCo AG (a consortium chaired by EQT), Abu Dhabi Investment Authority (ADIA), and Auba Investment Pte. Ltd. (all acting in concert as sellers) for an undisclosed sum.
Furthermore, L'Oréal and Galderma have agreed to collaborate on a strategic scientific partnership that will capitalize on both companies' unrivaled expertise: Galderma's in dermatological solutions, and L'Oréal's in skin biology, diagnostic tools, and evaluation techniques.
I am very pleased to announce this strategic investment and partnership with Galderma. It marks an ambitious step for L’Oréal, and true to our mantra of ‘seize what is starting,’ it allows us to explore partnering in the fast-growing aesthetics market, a key adjacency to our own pure beauty play said Nicolas Hieronimus, Chief Executive Officer of L’OREAL.
As the world leader in beauty and a pioneer in beauty technology, L'Oréal is increasingly investing in a more holistic approach that encompasses the entire beauty regimen. This strategy seeks to combine diagnostic tools, high-performance topical solutions, technological products, and aesthetic treatments to achieve new levels of performance by correcting, mending, preventing, anticipating, and intercepting the indications of skin ageing.
L'Oréal's strategic investment in Galderma reaffirms the company's strong growth trajectory over the last decade. Galderma, directed by CEO Flemming Ørnskov, M.D., MPH, and supported by the EQT consortium, has become a market leader in dermatology and injectable aesthetics. Today, Galderma provides a diverse range of dermo-cosmetics, dermatologic medicines, and best-in-class hyaluronic acid (HA) fillers, neuromodulators, and biostimulants.
Source: L’ORÉAL GROUPE
Comments